Search News Archives
Follow us on
Conferences | Events
Lab Bulletin Media Partners
Oxford Gene Technology

Oxford Gene Technology

Oxford Gene Technology

Products

Contact Oxford Gene Technology


If you have not logged into the website then please enter your details below.

All articles from Oxford Gene Technology

  OGT further Expands Global Direct Sales and Support into Asia-Pacific Region

cytocellOxford Gene Technology (OGT), The Molecular Genetics Company, has announced that it has expanded its direct sales of Cytocell Fluorescence In Situ Hybridisation (FISH) products to include the Asia-Pacific (APAC) region. OGT will provide customers in Singapore, Malaysia, Vietnam, Australia, and New Zealand with enhanced local sales and support services via established affiliates of Sysmex Corporation, as well as via continued collaboration with existing distributors...

 

  OGT Launches Enhanced SureSeq™ Interpret NGS Analysis Software

NGS dataPowerful, flexible and easy-to-use analysis solution gets the most out of NGS data. Oxford Gene Technology (OGT), The Molecular Genetics Company, has announced the launch of the eagerly-anticipated update to its SureSeq™ Interpret software, included with purchases of SureSeq NGS panels. Designed to help researchers effortlessly translate cumbersome NGS data into meaningful results, OGT has leveraged its renowned bioinformatics expertise to...

 

  OGT Expands Direct Sales and Support Infrastructure in Europe

OGT expands direct sales and support infrastructure in EuropeCustomers to benefit from Sysmex’s extensive operational footprint. Oxford Gene Technology (OGT), The Molecular Genetics Company, has announced that it is now directly selling Cytocell Fluorescence In Situ Hybridisation (FISH) products through several established affiliates of Sysmex Corporation in Europe following its acquisition last year....

 

  OGT Expands Custom NGS Cancer Panel Content and Readies Enhanced Software for Release

OGT expands custom NGS cancer panel content and readies enhanced software for releaseIncreased content provides even more flexibility for customisation. The Molecular Genetics Company, has expanded its SureSeq myPanel™ NGS Custom Cancer Panel content - now covering 120 fully optimised cancer related genes. The expanded content gives researchers even more freedom to customise their sequencing experiments, enabling focus on regions of interest, saving time...

 

  OGT Enhances Customer Experience with New Cytocell Website

OGT interactive chromosome search toolNew website makes it easier to access expert FISH advice. Oxford Gene Technology (OGT), The Molecular Genetics Company, has launched a new version of itsCytocell® fluorescence in situ hybridisation (FISH) probes website - designed to provide a wealth of information and advice, offer refined functionality, and be easy-to-use. Cytocell is well known for its complete and comprehensive range of FISH...

 

  OGT to be Acquired by Sysmex Corporation a Leading Provider of Haematology and In Vitro Diagnostics Products

Oxford Gene Technology (OGT), The Molecular Genetics Company, today announced that it has signed an agreement to be acquired by Sysmex Corporation (Sysmex), a Japanese in vitro diagnostic company.

OGTSysmex will acquire all of OGT’s shares, gaining access to OGT’s genetic analysis technologies and expertise in the cytogenetics domain. OGT will become a wholly owned subsidiary of Sysmex. Further terms of the agreement are not being disclosed....

 

  OGT’s Expanded NGS Cancer Panels Enable Sequencing of Difficult Genes

New SureSeq myPanel™ NGS Custom Cancer Panel content covers a wider range of cancer types with excellent coverage uniformity for confident results

OGT expanded NGS cancer panels enable sequencing of difficult genesOxford Gene Technology (OGT), The Molecular Genetics Company, has expanded its SureSeq myPanel™ NGS Custom Cancer Panel content. The expansion comes in response to NGS becoming ever more important for research into an increasing number of cancer types...

 

  OGT expands Cytocell sarcoma FISH probe range

Addition of three new sarcoma probes produces largest portfolio on the market

Cytocell Aquarius FOXO1Oxford Gene Technology (OGT), The Molecular Genetics Company, has expanded its range of Cytocell Aquarius® fluorescence in situ hybridisation (FISH) probes for pathology. OGT has introduced three new probes: FUS Breakapart and FOXO1 Breakapart, both carrying the CE-IVD label – and TFE3 Breakapart, for research use only. This expansion reinforces OGT’s commitment to providing the most comprehensive and up-to-date range available...

 

  OGT Releases Targeted NGS Panel to Study SNV and CNV in Familial Hypercholesterolemia

SureSeq myPanel™ NGS Custom FH Panels enable streamlined investigation of FH and customisation of content

OGT releases targeted NGS panel to study SNV and CNV in Familial HypercholesterolemiaOxford Gene Technology (OGT), The Molecular Genetics Company, has expanded its customisable SureSeq™ NGS panel range with the launch of the SureSeq myPanel™ NGS Custom FH Panel – allowing fast and cost-effective study of variants in familial hypercholesterolemia (FH). The new panel delivers both single nucleotide variation (SNV) and copy number variation (CNV) detection on a single small NGS panel assay...

 

  OGT Expands Cytocell FISH Probe Portfolio for Lung Cancers

New probes facilitate diagnosis and stratified treatment of NSCLC

OGT expands Cytocell FISH probe portfolio for lung cancersOxford Gene Technology (OGT), The Molecular Genetics Company, has launched two new CE-IVD labelled fluorescence in situ hybridisation (FISH) probes, further expanding its extensive lung cancer portfolio. The Cytocell Aquarius® ROS1 Plus Breakapart and RET Breakapart probes* specifically and accurately detect rearrangements in the genome associated with the most common form of lung cancer — non-small cell lung cancer (NSCLC)...

 

  Leading Experts Reveal how Exon-Focused Microarrays are Advancing Genetic Syndrome Research

OGT workshop at ESHG highlighted the impact of exon-level CNV analysis on accurate detection of genetic disorders

 Leading experts reveal how exon-focused microarrays are advancing genetic syndrome researchOxford Gene Technology (OGT), The Molecular Genetics Company, held an exclusive workshop exploring the power of exon-focused microarrays in enhancing genetic syndrome research at the recent European Human Genetics Conference (ESHG). Three expert clinical researchers from across the globe shared their knowledge of enhanced CNV detection with OGT’s CytoSure™ Constitutional v3 array, helping viewers...

 

  OGT Launches 9 New High-Intensity, Low-Background Cytocell Aquarius FISH Probes

Cytocell Aquarius® probe range expanded in response to high customer demand

New Cytocell AquariusOxford Gene Technology (OGT), The Molecular Genetics Company, has further expanded its extensive catalogue of fluorescence in situ hybridisation (FISH) products with nine new Cytocell Aquarius® probes. The range now includes ETV6 Proximal Probe Green, ETV6 Distal Probe Red, MPO Probe Red, TP53 Probe Green, NUP214 Probe Red, DEK Probe Green, TAS2R1 (5p15.31) Probe Green, Chromosome 9 Satellite III Probe...

 

  OGT Enhances NGS Results from FFPE Samples

New SureSeq™ FFPE DNA Repair Mix delivers excellent sequencing data for confident variant calling from minimal DNA input

Mean Target CoverageOxford Gene Technology (OGT), The Molecular Genetics Company, has introduced its SureSeq™ FFPE DNA Repair Mix — optimised to repair a broad range of damage in formalin-fixed, paraffin-embedded (FFPE) derived DNA. The mix effectively repairs DNA damage, improving library yields, on-target rates and mean target coverage, while removing fixation and storage artefacts and reducing the amount of starting...

 

  OGT Launches Cytocell FISH Probes for Glial Tumours

Cost-effective, ready-to-use kit enables reliable co-deletion investigations

CytocellOxford Gene Technology (OGT), The Molecular Genetics Company, has launched its CE-IVD labelled Cytocell Aquarius® 1p36/1q25 and 19q13/19p13 Deletion Probe Kit*, a cost-effective fluorescence in situ hybridisation (FISH) kit for the reliable investigation of glial tumours. Co-deletion of the 1p36.32 and 19q13.33 regions are frequently reported in many classes of gliomas.1,2 Moreover, the presence of a...

 

  OGT Develops New FISH Probes in ‘Outstanding’ Innovate UK Project

Cytocell Chromoprobe Multiprobe® non-human FISH probes set to benefit animal husbandry and research

OGT develops new FISH Oxford Gene Technology (OGT), The Molecular Genetics Company, has developed a new range of non-human fluorescence in situ hybridisation (FISH) probes, for pig, chicken and mouse. The probes were developed as part of an Innovate UK knowledge transfer partnership (KTP) funded project in collaboration with the University of Kent, and was given an ‘outstanding’ award reserved for the top 10% of KTP projects...

 

  OGT Expands Leading Constitutional Array Range - Enabling Exon-Level CNV and LOH Detection

Clinical researchers can now detect copy-neutral factors alongside powerful CNV detection with the addition of SNP probes to the popular CytoSure™ Constitutional v3 array content

CytoSure Constitutional v3 arrayOxford Gene Technology (OGT), The Molecular Genetics Company, has announced the launch of its new CytoSure Constitutional v3 +LOH array for comprehensive genetic analysis of developmental delay disorders. Alongside the latest content for exon-level copy number variation (CNV) coverage, research-validated single nucleotide polymorphism (SNP) probes facilitate detection of loss of heterozygosity (LOH), enabling insightful and...

 

  OGT Licenses SNP Probe Technology to Baylor Miraca Genetics Laboratories

Proprietary technology allows superior LOH detection in challenging samples

OGTOxford Gene Technology (OGT), The Molecular Genetics Company, has entered into a deal with Baylor Miraca Genetics Laboratories (BMGL), licensing the use of OGT’s proprietary single nucleotide polymorphism (SNP) array probe technology. This novel technology overcomes the limitations of restriction enzyme-based SNP probe approaches previously employed at BMGL for loss of heterozygosity (LOH) detection, allowing accurate array-based analysis of low...

 

  OGT Launches Cytocell FISH Probe for Bladder Cancer

Cost-effective, ready-to-use kit enables appropriate testing strategies for reliable diagnoses

CE-IVD labelled Cytocell AquariusOxford Gene Technology (OGT), The Molecular Genetics Company, has launched its CE-IVD labelled Cytocell Aquarius®P16/3c/7c/17c Probe Kit, a cost-effective, ready-to-use fluorescence in situ hybridisation (FISH) probe kit for non-invasive detection of bladder cancer — for sale in Europe. Bladder cancer is becoming increasingly prevalent, and in 2012 was reported as the 5th most common cancer in Europe1. While...

 

  OGT Helps Genetic Scientists Explore the Medical Exome

New whitepaper demonstrates how customisable, medically focused array designs complement NGS for clinical genetics research   

OGTOxford Gene Technology (OGT), The Molecular Genetics Company, has been speaking to genetic scientists, Dr Tracey Lewis (Associated Regional and University Pathologists [ARUP] Laboratories) and Dr Emily Farrow (Children’s Mercy Hospital), in a new whitepaper entitled “Examining the Medical Exome”. This whitepaper describes their experiences with OGT’s CytoSure™ Medical Research Exome Array and explores how this customisable array targets a variety of genetic disorders to...

 

  OGT Expands its Portfolio of Cytocell Pathology FISH Probes

Cost-effective pathology probes offer consistent and accurate results for a growing number of targets

cytocellOxford Gene Technology (OGT), The Molecular Genetics Company, is extending its portfolio of Cytocell® Pathology FISH probes with the addition of eight new probes. OGT offers the widest range of fluorescence in situ hybridisation (FISH) probes on the market, delivering a cost-effective and reliable solution for anyone engaged in FISH. The new additions to the Cytocell range include high-quality pathology FISH probes for 1q25, 1p36, 19p13, 19q13...

 

  OGT’s Popular ESHG Workshop Free to View Online

Learn about the next generation of microarrays in one of the best attended workshops of the conference

CytoSure Constitutional v3 arraysOxford Gene Technology (OGT), The Molecular Genetics Company, has made its European Human Genetics (ESHG) Conference workshop freely available to view online. The presentation, entitled “The Next Generation of Microarrays: Identifying a Broader Range of Genetic Syndromes Using Exon–Focussed Array Designs”, took place at the ESHG conference in Glasgow, UK on 8th June 2015. OGT also launched its CytoSure™ Constitutional v3 Arrays at...

 

  OGT Launches New Arrays for Developmental Disorders at ESHG

High-resolution exon-focused arrays with enhanced content from the Deciphering Developmental Disorders study

Cytosure Interpret SoftwareOxford Gene Technology (OGT), The Molecular Genetics Company, is today launching a new range of arrays at the European Society of Human Genetics (ESHG) Conference in Glasgow, UK, that are dedicated to elucidating the underlying causes of developmental delay. OGT’s unique Cytosure™ Constitutional v3 arrays have been developed following its recent licence agreement with the Wellcome Trust Sanger Institute to access the...

 

  New Test Could Identify Resistant Tuberculosis Faster

The time needed to genetically sequence the bacteria causing tuberculosis (Mtb) from patient samples has been reduced from weeks to days using a new technique developed by a UCL-led team.

OGTThis could help health service providers to better treat disease, control transmission of this infection, and monitor outbreaks. Tuberculosis (TB) disease rates in some parts of London are as high as in Sub-Saharan Africa, and drug-resistant strains are becoming increasingly common. These require specific treatments, and if doctors know that a bug is resistant they can start therapy earlier, often leading to better outcomes. Whole genome sequencing reveals the complete...

 

  The Role of NGS in Stratified Cancer Medicine

Oxford Gene Technology (OGT), The Molecular Genetics Company, has teamed up with clinical research experts in a new article available online, discussing the role of next generation sequencing (NGS) in cancer medicine.

Dr George BurghelThe article, entitled “The role of NGS in stratified cancer medicine”, presents a valuable resource to better understand the present and the future of NGS in stratified cancer medicine, detailing the most relevant aspects of this revolutionary technology. A key focus of current cancer research is developing the use of stratified medicine. The approach is highly advantageous in guiding effective therapy as it profiles the genetic makeup of individual tumour samples...

 

  Sheffield NHS Lab Discusses Move to CytoSure Arrays

New case study follows the successful adoption of OGT’s CytoSure™ platform at Sheffield Children's NHS Foundation Trust  

Chromosome summeryOxford Gene Technology (OGT), The Molecular Genetics Company, explores how Sheffield Children's NHS Foundation Trust has seamlessly transferred to its CytoSure™ ISCA 8x60k platform, in a new case study entitled Evaluating and switching to CytoSure microarrays. As the result of a highly stringent National Health Service (NHS) tender for the supply of oligo-based cytogenetics research arrays, CytoSure was selected based on...

 

  OGT Launches Medical Research Exome Array at ASHG

Oxford Gene Technology (OGT), The Molecular Genetics Company, has launched its CytoSure™ Medical Research Exome Array at the 64th Annual Meeting of the American Society of Human Genetics (ASHG)

 Exome Array at ASHG Developed with leading molecular genetics experts at Emory University, the new array is highly targeted and exon-focussed, enabling the accurate detection of medical research relevant microdeletions and microduplications. The high-density array (1x1M) contains over 4,600 hand-curated genes, which have been grouped into disease- and syndrome-specific panels. This research-validated gene content can also be customised for...

 

  OGT Launches High-Resolution, High-Throughput PGS Array

Oxford Gene Technology (OGT), The Molecular Genetics Company, has announced the launch of a new high-resolution, high-throughput pre-implantation genetic screening (PGS) microarray aimed at improving embryo screening for in vitro fertilisation (IVF).

CytoSure EmbryoThe CytoSure™ Embryo Screen Array offers eight arrays of 60,000 spots for high-resolution genome-wide aneuploidy and copy number detection in pre-implantation embryos. The microarray can screen up to 14 embryos on a single slide, which is particularly useful in embryo banking — a common procedure for advanced maternal age samples — enabling the confident identification of the best embryo for implantation.

 

  OGT to Sell Cytocell Products Direct in North America

Oxford Gene Technology (OGT), The Molecular Genetics Company, has announced that following its acquisition of Cytocell in March, it will directly sell Cytocell products to the North American market.

cytocellNew and existing Cytocell customers in North America will now benefit from OGT’s expert and experienced sales and support infrastructure, which will be further enhanced through additional appointments in the coming months. OGT’s acquisition of Cytocell saw the addition of a portfolio of Fluorescence In Situ Hybridisation (FISH) probes to its CytoSure™ cytogenetics array and Genefficiency™ next generation sequencing products and...

 

  Achieving High Quality Microarray Results

Oxford Gene Technology (OGT), The Molecular Genetics Company, has released a new application note detailing the technical evaluation of two DNA labelling kits, where OGT’s CytoSure Genomic DNA Labelling Kits were found to be quicker and more accurate than a leading alternative.

CytoSure Labelling Kit Achieving efficient and uniform labelling of both test and reference DNA samples is critical for aCGH studies, enhancing data accuracy and interpretation. By ensuring greater accuracy, OGT’s kits vastly improve the identification of breakpoints and even the smallest aberrations, providing robust and invaluable insights into the underlying cause of genetic disorders... 

 

  An Integrated Approach to Clinical Genetics Research

Oxford Gene Technology (OGT), The Molecular Genetics Company, has produced a new whitepaper titled ‘Comprehensive genomic analysis – complementing sequencing with high-resolution CNV detection’.

oxford gene technologyThe free, downloadable whitepaper provides researchers with an opportunity to explore the latest strategies in the genomic characterisation of complex disorders, and to discover how, when used alongside sequencing, microarrays play a vital role in delivering accurate detection of point mutations and single exon copy number aberrations. The new whitepaper explains how utilising a range of available tools builds a more complete picture of inherently complex genetic disorders...

 

  New Updates to Leading aCGH Data Analysis Software

OGT releases new CytoSure™ Interpret Software to enhance CNV detection

CytoSure Interpret SoftwareOxford Gene Technology (OGT), The Molecular Genetics Company, is pleased to announce the latest version (4.5.3) of its class-leading CytoSure™ Interpret Software. Complimentary with all CytoSure array purchases, CytoSure Interpret Software is a powerful and easy-to-use package for the analysis of aCGH data, the gold-standard for copy number variation (CNV) detection. Offering an impressive combination of advanced features, including Automatic Aberration Classification, the software allows the choice of standardised or customised user-defined data analysis....

 

  OGT and Emory Genetics Laboratory develop new molecular arrays

Emory’s Professor Madhuri Hegde to discuss OGT’s new molecular arrays at ACMG 2014

CytoSure Molecular ArraysOxford Gene Technology (OGT), The Molecular Genetics Company, has expanded its range of research-validated CytoSure Molecular Arrays to investigate DNA copy number variation (CNV) underlying a variety of genetic disorders. Designed and optimised in collaboration with experts at Emory Genetics Laboratory (EGL; Atlanta, USA), the arrays are the ideal complement to DNA sequencing, providing a particularly powerful tool for investigating the variety of aberrations underlying genetic disorders. Professor Madhuri Hegde, Professor of Human Genetics at Emory University School of Medicine, will discuss the design and application of these arrays at the American College of Medical Genetics (ACMG) meeting on Thursday 27 March 2014...

 

  NHS awards significant cytogenetics tender to OGT

Quality-driven tender selects OGT after extensive validation 

NHS awards significant cytogenetics tender to OGTOxford Gene Technology (OGT), provider of innovative genetics research and biomarker solutions to advance molecular medicine, has been awarded a significant tender by the UK National Health Service for the supply of oligo-based arrays for cytogenetics. Involving the cooperation of a number of health authorities, the tender’s comprehensive validation process sets an excellent example for future procurement procedures...

 

  New whitepaper highlights impact of NGS target enrichment assay choice

OGT provides insight on NGS enrichment optimisation

New whitepaper highlights impact of NGS target enrichment assay choiceOxford Gene Technology (OGT), provider of innovative genetics research and biomarker solutions to advance molecular medicine, has produced a free whitepaper titled ‘The importance of enrichment assay choice and optimisation for confident variant detection.’ The paper investigates the main strategies employed to optimise target enrichment for next generation sequencing (NGS) assays, assisting researchers to make informed decisions when designing studies...

 

  Oversubscribed NGS and aCGH workshop now available online

OGT’s ASHG 2013 workshop highlights the need for comprehensive genomic analysis

Molecular Array Workshop

Oxford Gene Technology (OGT), provider of innovative genetics research and biomarker solutions to advance molecular medicine, has made a recording of its recent American Society of Human Genetics (ASHG) workshop available to watch online. The oversubscribed workshop, titled “Complementing next generation sequencing experiments with high-resolution copy number variation detection”, was recorded at the meeting in Boston (US) on the 25th of October 2013...

 

  A snapshot of the NGS market - user views

OGT publishes survey results

New whitepaper compares targeted resequencing strategies

Oxford Gene Technology (OGT), provider of innovative genetics research and biomarker solutions to advance molecular medicine, has released the results from a recent survey of researchers using next generation sequencing. The survey was designed to investigate current trends in NGS usage and determine future demands; to aid OGT in continuing to deliver high-quality, up-to-date services and provide insightful, relevant customer resources...

 

  Free NGS report demo — Bypass the data bottleneck with Genefficiency services

Rapidly identify meaningful results with OGT’s Genefficiency™ NGS Report

NGS report demo — Bypass the data bottleneck with Genefficiency services

Oxford Gene Technology (OGT), provider of innovative genetics research and biomarker solutions to advance molecular medicine, is offering the research community a snapshot of its user-friendly Genefficiency™ NGS Variant Analysis Report software, with the release of a free-to-download demo version. The interactive report efficiently manages the complete data analysis process for NGS workflows and delivers fully annotated data, allowing the identification of meaningful results in just a few simple mouse clicks...

 

  New whitepaper compares targeted resequencing strategies

OGT provides insight into choice of NGS methods

New whitepaper compares targeted resequencing strategies

Oxford Gene Technology (OGT), provider of innovative genetics research and biomarker solutions to advance molecular medicine, has produced a new, free-to-download whitepaper titled ‘When to use targeted resequencing — Choosing the right NGS method.’ The paper aims to assist researchers when planning NGS strategies by providing a detailed review of the major resequencing methods. Comparing and contrasting method suitability, the paper also examines the significant impact of data analysis, as well as time and cost considerations...

 

  OGT Expands NGS Offering with Targeted Familial Sequencing and Analysis

Introductory 3 for 2 exome sequencing and analyses offer

OGT Pipeline

Oxford Gene Technology (OGT), provider of innovative genetics research and biomarker solutions to advance molecular medicine, has extended its high-quality whole exome sequencing services with a targeted Familial Sequencing and Analysis Service. Ideal for investigators of inherited disease, the new service delivers multi-genome analysis of related samples for the detection of causative, de novo and disease susceptibility mutations. With a fully optimised workflow, OGT offers the entire targeted next generation sequencing pipeline, from project design through to end-point mutation discovery and extensive variant annotation...

 

  OGT releases new CytoSure microarray for research into haematological and solid cancers

Simultaneous detection of CNVs, SNPs and LOH on a single array using any reference sample

OGT CytoSure microarray

Oxford Gene Technology (OGT), provider of innovative genetics research and biomarker solutions to advance molecular medicine, has released a new microarray to improve the accuracy and efficiency of cancer research. The CytoSure™ Cancer +SNP array (4x180k) combines long oligo array comparative genomic hybridisation (aCGH) probes with fully validated single nucleotide polymorphism (SNP) content, providing the superior detection of both copy number variations (CNVs) and loss of heterozygosity (LOH) on a single chip. The array has been optimised in collaboration with Professor Jacqueline Schoumans from the Lausanne University Hospital in Switzerland, an expert in both aCGH and cancer genomics...

 

  New application note examines the application and benefits of combined aCGH +SNP arrays

Oxford Gene Technology (OGT), provider of innovative genetics research and biomarker solutions to advance molecular medicine, has produced a new, free-to-download application note on combined array comparative genomic hybridisation (aCGH) and single nucleotide polymorphism (SNP) arrays.

Detecting CNVs and ROH on a single array is streamlining the workflow

The application note, titled ‘Detecting copy number variants and runs of homozygosity on a single array — challenges and applications’ aims to support researchers in navigating this combined approach for the simultaneous detection of copy number variations (CNVs) and runs of homozygosity (ROH). aCGH has established itself as the “gold-standard” platform for array-based CNV detection. Recent advances have enabled the combination of aCGH probes for CNV detection with probes able to detect SNPs...

 

  Oxford Gene Technology supports the future of UK life science research

Placement student, David Blaney achieves UK Life Sciences Placement of the Year award

David Blaney winning awardOxford Gene Technology (OGT), provider of innovative genetics research and biomarker solutions to advance molecular medicine, is proud to announce the achievements of placement student David Blaney. Following a nomination by the company, David earned this year’s BBSRC-sponsored Placement of the Year award. The award was part of the inaugural Cogent UK Life Science Skills Awards event, which took place on the 16th May and saw winners take to the stage to receive awards across ten categories...

 

  OGT to hold live webinar on NGS and data analysis strategies for cancer research

Optimising next generation DNA and RNA sequencing studies

OGT to hold live webinar on NGS and data analysis strategies for cancer researchOxford Gene Technology (OGT), provider of innovative genetics research and biomarker solutions to advance molecular medicine will hold a live webinar entitled ‘Effective cancer sequencing and analysis strategies’ on Thursday 31st January 2013 at 3:00pm (GMT). Dr Simon Hughes, Team Leader Cancer R&D, OGT and Dr Daniel Swan, Senior NGS Computational Biologist, OGT will discuss next generation DNA and RNA sequencing for cancer research studies including choosing the best sequencing strategy, experimental design for targeted resequencing, types of samples, and the use of OGT’s NGS browser for the effective and rapid identification of genetic aberrations such as copy number variation, loss of heterozygosity and splice variants...

 

  Share a snowman with OGT to win an Amazon Kindle Fire tablet

Build and dress a snowman with OGT’s interactive Share-a-Snowman Game

Share-a-Snowman

Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, invites you to get into the spirit of sharing this holiday season with its interactive Share-a-Snowman Game. In true festive style, OGT has once again decided to send an electronic Christmas card and will be making a donation to a number of charities in lieu of sending paper cards. The e-card will feature the snowman builder game; create your own snowman and send it to your friends and colleagues...

 

  OGT to host live Webinar on the optimal strategies for exome sequencing and analysis

Streamlined strategy and analysis that delivers meaningful results

GE SequencingOxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, will host a live Webinar on Thursday 6th September (3 pm BST) hosted by Dr Daniel Swan, Senior NGS Computational Biologist at OGT. Entitled "Exome sequencing and analysis strategies that deliver meaningful results", the Webinar will provide insight and advice for optimising exome sequencing studies, taking advantage of the knowledge and experience routinely offered as part of OGT's comprehensive GenefficiencyTM exome sequencing and analysis service...

 

  OGT to Host Cancer and Rare Disease Analysis Workshop at ESHG 2012 Customer and company experts to discuss identifying causative mutations using arrays and sequencing

Oxford Gene Technology (OGT)Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, will host a workshop at this year's European Society of Human Genetics (ESHG) conference in Nürnberg, Germany (June 23-26). The session, entitled "Utilising arrays and next generation sequencing (NGS) to identify causative mutations in cancer and rare disease samples", will take place on Saturday 23rd June...

 

  New application note explores the optimisation of targeted DNA sequencing Improving custom bait design to increase accuracy, sensitivity and coverage depth

Fishing for variantsOxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, has released a new application note exploring the optimisation of targeted DNA sequencing. Entitled, "Fishing for variants in the deep end of the gene pool", the document discusses how the intelligent design of custom bait probes can significantly improve data quality by decreasing off-target noise...

 

  OGT Releases Major CytoSure Software Update Oxford Gene Technology (OGT)Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, has released a major new update to its CytoSureTM Interpret Software for array Comparative Genomic Hybridisation (aCGH) analysis. By utilising an entirely new relational database design, the software now allows sample data to be stored and analysed in accordance to its relationship with other data. For example, samples can be segregated into different projects by sample type or by user, thereby simplifying analysis...

 

  Fifth annual Rare Disease Day highlights the need for more research Oxford Gene Technology (OGT)Today is the 5th annual Rare Disease Day, designed to raise global awareness amongst the general public and policy makers about rare diseases and their impact on patient's lives. Information recently released by EURORDIS , the organiser of Rare Disease Day 2012, suggests that "due to the low prevalence of each disease, medical experts are rare, knowledge is scarce, care offering inadequate, and research limited." To meet the need for further research into this area, Oxford Gene Technology (OGT), a provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, has recently announced a dedicated rare disease version of its GenefficiencyTM Targeted Sequencing Service...

 

  OGT to Exhibit and Present at Molecular Medicine Tri-Con 2012 Oxford Gene Technology (OGT)Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, will be exhibiting and presenting its biomarker discovery service at the Molecular Medicine Tri-Con in San Francisco, California (19th-23rd February 2012). The conference, organized by the Cambridge Healthtech Institute, will include an OGT presentation entitled "Integrated Biomarker Discovery: Multi-Method Approach to Enable Early Biomarker Success"...

 

  OGT founder Professor Sir Ed Southern awarded the 2011 MRC Millennium Medal Professor Sir Ed SouthernProfessor Sir Ed Southern, founder of Oxford Gene Technology (OGT), a provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, has been awarded the 2011 Medical Research Council (MRC) Millennium Medal. Sir Ed becomes one of only four researchers to have received the prize since it was inaugurated in the year 2000, which recognises an MRC-funded scientist whose outstanding research has made a major contribution towards the health and wealth of our society...

 

  Oxford Gene Technology and Abcodia form Partnership Oxford Gene TechnologyOxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, has today announced a collaborative agreement with Abcodia, a specialist company engaged in the validation and discovery of biomarkers of cancer and other age-related diseases, aimed at improving the early detection of pancreatic cancer. As part of this collaboration, Abcodia will provide access to its large prospective serum biobank, to harness samples taken from individuals up to 7 years before the diagnosis of pancreatic cancer...

 

  OGT sequencing workshop at ESHG 2011 attracts over 130 delegates Oxford Gene Technology (OGT)Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, recently announced details of its new targeted sequencing service as part of a workshop at the European Society of Human Genetics Conference (ESHG 2011) in Amsterdam, The Netherlands. The workshop, entitled "Adding value through analysis", attracted over 130 delegates and featured presentations from OGT team members discussing the key elements of the service...

 

  Company receives £1.16m award from the UK’s Technology Strategy Board Oxford Gene Technology Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, has today announced that it has received a funding award of £1.16 million from the UK government-backed Technology Strategy Board. As part of the project, OGT will develop a tumour profiling assay based on targeted panel enrichment and next generation sequencing (NGS)...

 

  OGT announces new targeted next generation sequencing service GE Sequencing LogoOxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, has today announced the release of its next generation targeted sequencing service. With an emphasis on flexibility, expert project design and advanced data analysis, the new offering takes advantage of OGT's high-quality processes and in-house bioinformatics experience to provide the most complete targeted sequencing solution available...

 

  How to choose a microarray service provider Oxford Gene Technology Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, has recently published a whitepaper entitled "10 essential questions to ask your microarray service provider". The document, which is available to download at OGT's website, suggests the 10 most important questions a researcher should ask when identifying which microarray service best meets their experimental requirements...

 

  OGT Awarded ISO/IEC 17025:2005 Accreditation, Signifying Technical Expertise Oxford Gene TechnologyOxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, today announced that its GenefficiencyTM and CytoSureTM array comparative genomic hybridization (aCGH) services have been accredited as meeting ISO/IEC 17025:2005 international standards by the United Kingdom Accreditation Service (UKAS). The award underlines the superior level of expertise and quality control in the company's laboratories and allows identification of OGT as a high-quality supplier of fully validated aCGH services.

 

  OGT expands CytoSure aCGH product range OGTOxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, has expanded its CytoSureTM product range to include high-throughput genomic DNA labelling kits and sample tracking spike-ins. These new products will further streamline workflow and minimise sample tracking errors when performing array comparative genomic hybridisation (aCGH).

 

  OGT Announces Major Role in Large Scale Diabetes Study Oxford Gene TechnologyOxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, has today announced details of a major project with the University of Virginia Center for Public Health Genomics. In a groundbreaking study, Professor Stephen Rich, Director of the centre, will utilise OGT's GenefficiencyTM aCGH microarray screening service to investigate the relationship between genome structural variation and susceptibility to type 1 (T1) diabetes.

 

  OGT Grants DNA Sequence Variation Licence to Biotype Diagnostics GmbH Oxford Gene Technology (OGTOxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, and Biotype Diagnostics GmbH are pleased to announce the completion of a licence agreement granting Biotype access to OGT patents for the detection of DNA sequence variations. The licence, which will remain valid for the lifetime of the patents, provides Biotype with certain rights with respect to SNP genotyping

 

  Over 100 Delegates attend OGT’s aCGH Workshop at ASHG 2010 OGTOxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, attracted over 100 delegates to its workshop during the recent American Society of Human Genetics Conference (ASHG 2010) in Washington, USA. Entitled "From Genomic Studies to Cytogenetics Research - An Integrated and Standardised Solution", those present heard leading researchers talk about how OGT's array comparative genomic hybridisation (aCGH) solutions are helping to advance research into disease and cytogenetics

 

  OGT Announces Exhibitor Workshop at ASHG 2010 in Washington OGT LogoOxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, has announced the details of its upcoming exhibitor workshop at the American Society of Human Genetics (ASHG) Annual Meeting 2010, to be held in Washington DC. The presentation, entitled "From Genomic Studies to Cytogenetics Research - An Integrated and Standardised Solution", will take place on Thursday 4th of November in Room 144A (Level 1) of the Convention Center, between 13:00 and 14:00

 

  OGT Presents Promising Prostate Cancer Biomarker Panel Results at AACR Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, has presented potentially highly significant, preliminary data on the development of a panel of biomarkers for the diagnosis of prostate cancer. In the pilot study, a set of biomarkers was identified which can distinguish prostate cancer from control samples with both sensitivity and specificity above 90%, far higher than existing diagnostic tests.

 

  OGT Receives ISO/IEC 27001:2005 Accreditation Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, today announced that it has been certified compliant with ISO/IEC 27001:2005, an international information security management standard.

 

  OGT Introduces Unique CNV Array with Whole Chromosome Uniparental Disomy (UPD) Detection Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, has today introduced the groundbreaking CytoSure ISCA UPD 4 x 180k array.

 

  OGT Attracts Over 200 Delegates to its aCGH Satellite Meeting at ESHG 2010 Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, has announced that over 200 delegates came to its satellite meeting during the recent European Human Genetics Conference (ESHG 2010) in Gothenburg, Sweden. Entitled From disease to cytogenetics research - An integrated CNV analysis platform from OGT, the delegates heard presentations from leading researchers on how OGT's array comparative genomic hybridisation (aCGH) solutions can help advance disease and cytogenetics research.

 

  OGT Awarded ISO 9001:2008 for its Management Systems Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, today announced that the management system at its Oxford, UK Headquarters has been certified to BS EN ISO 9001:2008 by the British Standards Institution (BSI), one of the world's leading certification bodies.

 

  OGT and Cartagenia Collaborate in Automated Aberration Data Transfer Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, today announced that its CytoSureTM Interpret Software can now seamlessly transfer array comparative genomic hybridisation (aCGH) aberration data directly to Cartagenia's BenchTM constitutional cytogenetics platform.

 

  OGT Announces Details of aCGH Satellite Meeting at ESHG 2010 in Sweden Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, has announced the theme and times of its satellite meeting during the European Human Genetics Conference (ESHG) 2010 in Gothenburg, Sweden, June 12-15. Entitled "From disease to cytogenetics research - An integrated CNV analysis platform from OGT", the meeting will take place on Saturday 12 June in Room H1, from 12:00-13:30.

 

  OGT Signs Kreatech as Exclusive Distributor for CytoSure in France Oxford Gene Technology (OGT), the pioneer of microarray-based technologies, has today announced that it has signed an exclusive distribution agreement with Kreatech Diagnostics (Amsterdam, The Netherlands). The deal will enable Kreatech Diagnostics to sell OGT's CytoSureTM products throughout France, providing customers with a comprehensive aCGH solution.

 

  OGT Named by Agilent as the First High-Throughput Microarray Certified Service Provider Following almost two years as an Agilent microarray Certified Service Provider, Oxford Gene Technology (OGT) and Agilent Technologies, Inc. (NYSE: A), today announced that OGT is the first company to be named as a High-Throughput Certified Service Provider (HT CSP) for Agilent microarrays.

 

  OGT launches new ISCA-endorsed CytoSure aCGH arrays for detecting disease and syndrome-related aberrations Oxford Gene Technology (OGT), the pioneer of microarray-based technologies, has introduced three new CytoSureTM ISCA aCGH arrays to meet all resolution, multiplexing and budget requirements.

 

  OGT Introduces New Array CGH Interpretation Software Oxford Gene Technology (OGT), the pioneer of microarray-based technologies, has introduced its new CytoSure™ Interpret software, for faster and easier translation of oligo aCGH data into meaningful results.

 

  OGT expands CytoSure aCGH offering with high resolution Duchenne Muscular Dystrophy array Oxford Gene Technology (OGT), the pioneer of microarray-based technologies, has introduced the high resolution CytoSure™ DMD array. Featuring a 4x44k format and dense probe coverage of the DMD gene region, this new array offers increased confidence in detecting deletions and duplications within the DMD gene.